Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01508910 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
A Phase 3 study, sponsored by Lisata Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 291
- Enrollment target
NCT01508910: Completed Phase 3 study, sponsored by Lisata Therapeutics.
NCT01508910 is a Phase 3 study that has completed, run by Lisata Therapeutics. The registered enrollment target is 291 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01508910, a Phase 3 study, has completed, sponsored by Lisata Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 291 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and efficacy of targeted intramyocardial delivery of Auto-CD34+ cells for increasing exercise time and amelioration of anginal symptoms in subjects with refractory angina and chronic myocardial ischemia.
Primary Outcome
Baseline (BL) is the average of the two total exercise times measured during the screening period.
Interventions
- OTHER Standard of care
- BIOLOGICAL Auto-CD34+ cells
- BIOLOGICAL Placebo: Diluent used to suspend Auto-CD34+ cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
What the finished NCT01508910 record still lists
NCT01508910 is an interventional study that assigns participants to a tested intervention. The registered 291 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 3 interventions - of which Standard of care is the first listed.
NCT01508910 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01508910 about?
NCT01508910 is a clinical study titled "Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina". The purpose of the study is to assess the safety and efficacy of targeted intramyocardial delivery of Auto-CD34+ cells for increasing exercise time and amelioration of anginal symptoms in subjects with refractory angina and chronic myocardial ischemia.
What is the current status of trial NCT01508910?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 291 participants. The study started on 2012-04. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01508910?
The interventions under investigation include: Standard of care (OTHER), Auto-CD34+ cells (BIOLOGICAL), Placebo: Diluent used to suspend Auto-CD34+ cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01508910?
This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01508910's enrollment target sits among peer trials
291 1168th of 2000 higher than 830 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02074839 · 291 participants · Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- NCT03769766 · 291 participants · Phase 3
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
- NCT06563479 · 291 participants · Phase 3
A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia